Business Wire Industry News

Friday, July 17, 2026

ME Therapeutics Closes Over-Subscribed Private Placement

VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has closed its previously announced non-brokered private placement for aggregate proceeds of $576,500.60 (the “Financing”). Closing of the Financing The Financing consisted of the issuance of 33

Thursday, July 16, 2026

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid (“detalimogene”) if approved. Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk no

Thursday, July 16, 2026

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. “The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic and differentiated optic portfolio to suit a wide range of patients,” said Wayne Caulder, vice president and general manager, North America Surgi

Wednesday, July 15, 2026

Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study

Tuesday, July 14, 2026

Meridian Bioscience Announces Health Canada License for Alethia® CMV Assay

CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Health Canada has granted a license for its Alethia® CMV assay. The addition of CMV expands Meridian's existing Alethia menu, which includes C. difficile, Group A Strep, Group B Strep, malaria, Mycoplasma, and pertussis assays. This clearance expands Meridian's molecular diagnostic offerings in the Canadian market. The Alethia pla

Tuesday, July 14, 2026

Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent unmet medical needs. Previously, ridinilazole was evaluated in Summit’s Phase III Ri-CoDIFy study for the tre

Tuesday, July 14, 2026

BioTalent Canada and Fairleigh Dickinson University Vancouver Partner to Strengthen Life Sciences Talent Development

OTTAWA, Ontario & VANCOUVER, British Columbia--(BUSINESS WIRE)-- #ait--BioTalent Canada and Fairleigh Dickinson University (FDU) Vancouver have announced a new partnership designed to advance workforce development, deepen industry engagement and support growth in British Columbia’s life sciences sector. The partnership brings together BioTalent Canada’s expertise in bioscience workforce development, labour market intelligence, skills development and employer engagement with FDU Vancouver’s growing foc

Tuesday, July 14, 2026

Actineer Achieves Sustainable Radium-226 Recycling to Advance Reliable Commercial-Scale Production of Actinium‑225 for Global Radiopharmaceutical Programs

CHALK RIVER, Ontario--(BUSINESS WIRE)--Actineer, a joint venture between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM), today announced the successful completion of a closed-loop process to recycle Radium‑226 (Ra-226), the essential precursor material of Actinium-225 (Ac-225), a rare medical radioisotope that is highly sought-after for its role in the development of targeted alpha therapy (TAT) in oncology. This critical milestone supports reliable, long-term

Monday, July 13, 2026

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi

Monday, July 13, 2026

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Ann

Friday, July 10, 2026

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachu

Friday, July 10, 2026

Cord Blood Council Earns 501(c)(3) Nonprofit Status and Opens Public Donations to Strengthen the Nation’s Public Cord Blood Banks

SEATTLE--(BUSINESS WIRE)--The Cord Blood Council (CBC), a capacity-building nonprofit supporting the nation’s public cord blood banks, today announced that it has received federal 501(c)(3) tax-exempt status and is now accepting tax-deductible donations from the public. Gifts can be made at cbcouncil.org/donate. The milestone broadens the community support behind the organization’s mission: strengthening and unifying the public cord blood banks that supply the life-saving stem cells used in tra

Thursday, July 9, 2026

Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller Phase 1/2a study following 28 days of topical administration. Based on the totality of the data, the company has dec

Thursday, July 9, 2026

BenchSci Names Former Pfizer R&D Chief Dr. Mikael Dolsten as Chairman of the Board

TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced the appointment of Dr. Mikael Dolsten, M.D., Ph.D., as Chairman of its Board of Directors, effective June 2026 — the first Chairman role in the company's history. Dr. Dolsten joined BenchSci's board as a director in July 2025, a year after retiring as Chief Scientific Officer and President of Pfizer Research & Development, where he could have taken a board seat at ne

Wednesday, July 8, 2026

U of T, McMaster Announce Early-Stage Life Sciences Venture Fund With Genesys Capital

TORONTO--(BUSINESS WIRE)--In a move that will provide a major boost to life sciences startups in Ontario and the Canadian health economy overall, the University of Toronto, McMaster University and Venture Ontario announced they are joining with veteran investor Genesys Capital to create a new life sciences venture capital fund. The Genesys University Seed Fund will be a vital source of early-stage capital for fledgling startups, helping to translate promising university-based commercial ideas i

Wednesday, July 8, 2026

STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development

VANCOUVER, British Columbia & TORONTO--(BUSINESS WIRE)--STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) starting materials, giving cell therapy developers worldwide a faster, lower-risk path from research to the clinic. Under the agreement, STEMCELL will manufacture and distribute research-use-only (RUO) iPSC lines derived directly from LineaBio's

Tuesday, July 7, 2026

Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough

LAVAL, Québec--(BUSINESS WIRE)-- #AIInDrugDevelopment--Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in

Tuesday, July 7, 2026

Menopause Unfiltered by Genestra Brands

TORONTO--(BUSINESS WIRE)-- #genestrabrandsca--Genestra Brands introduces a clinically backed formula designed to support multiple aspects of the menopause transition

Tuesday, July 7, 2026

Anaergia Australia Pty Ltd. to Supply Advanced Anaerobic Digestion Technology for Goodness Grown Facility in Australia

TONGALA, Australia and BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG; OTCQX: ANRGF), through its subsidiary Anaergia Australia Pty Ltd., entered into a contract with RF Corval Pty Ltd. (“Corval”) to deliver proprietary technology and equipment for an advanced anaerobic digestion facility at the Goodness Grown farm production site in Tongala, Australia. The facility is being designed to process up to 120,000 tonnes per year of mixed agricultural and

Monday, July 6, 2026

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to eight newly hired non-executive employees consisting of options to purchase an aggregate of 169,740 common shares of the Company (the "Options") with effective grant dates of July 6, 2026

Monday, July 6, 2026

PharmaEssentia Announces Health Canada Approval of BESREMi® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that its wholly owned subsidiary, FORUS Therapeutics Inc, has received a Notice of Compliance (NOC) authorizing BESREMi® (ropeginterferon alfa-2b) for the treatment of adults with polycythemia vera (PV). BESREMi® is expected to become commer

Monday, July 6, 2026

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS® and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR)

Wednesday, July 1, 2026

MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced the filing of European patent application No. EP26187897.9, directed to high-dimensional data structures for biological subsequences and property inference. The application is intended to protect the enriched biological representation architecture that underpins MindWalk's HYFT® Technology, its ReefIQ™ biological context layer, and its LensAI™ reasoning workflows. The fi

Wednesday, July 1, 2026

New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced new findings from its third annual State of Dry Eye survey, which reveals that the impact of dry eye can extend beyond the burden of physical symptoms, affecting how patients view their emotional health and wellbeing. This year’s survey was conducted online by The Harris Poll in May 2026 among 1,000 dry eye suff

Tuesday, June 30, 2026

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution

RALEIGH, N.C. & LONDON--(BUSINESS WIRE)--Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innova

Tuesday, June 30, 2026

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™

LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Thera

Tuesday, June 30, 2026

Exact Imaging Expands U.S. Commercial Team to Meet Growing Demand for Its Micro-Ultrasound Technology for Prostate Cancer

MARKHAM, Ontario--(BUSINESS WIRE)-- #medtech--Exact Imaging, the creator of a first-of-its-kind high-resolution micro-ultrasound system for targeted prostate cancer biopsies, today announced expansion of its U.S. commercial team as the company continues to build momentum across major health systems.The expansion includes the promotion of Tim Heyer to vice president, North American Sales. Heyer is a U.S. Marine Corps veteran with 35 years of experience in medical device sales and service, having helped laun

Monday, June 29, 2026

QT Imaging’s CEO Presents Sports Shiftmaker Award to Tennis Champion and Breast Cancer Survivor Martina Navratilova During Wimbledon Week

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (Nasdaq: QTI) (“QT Imaging” or the “Company”), a medical device company engaged in the research, development and commercialization of innovative body imaging systems, announces that CEO Dr. Raluca Dinu presented the Shiftmaker Award to Martina Navratilova at the Sports Shiftmaker Awards ceremony last weekend and is participating in a series of thought-provoking women’s health panels during Wimbledon week in London. The panels and ceremo

Thursday, June 25, 2026

Nomic joins the HESI Global OASIS Consortium to Advance Human-Relevant Safety Assessment Through Proteomics

MONTREAL--(BUSINESS WIRE)--Nomic Bio Inc., today announced they will partner with the Health and Environmental Sciences Institute’s (HESI Global) Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium to identify biomarker signatures for liver toxicity using large-scale protein profiling of human liver-derived cell models. The OASIS Consortium is designed to support more predictive, efficient, and human-relevant approaches to compound safety assessment, consistent with the grow

Wednesday, June 24, 2026

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides (TG) and the risk of acute pancreatitis in adults with severe hypertriglyceridemia (sHTG: TG greater than or equal to 500 mg/dL). TRYNGOLZA is available in a 50 mg or 80 mg dose and is self-administered once monthly via an autoinjector. sHTG is characterized by an increased

Wednesday, June 24, 2026

Linesight: Canada’s Construction Growth Continues in 2026, but Power, Planning, and Workforce Constraints Are Shaping Delivery

TORONTO--(BUSINESS WIRE)--Canada’s construction industry is forecast to grow by 2.6% in 2026, supported by public investment and continued activity across data centers, life sciences, infrastructure, and high-tech industrial projects, according to Linesight’s latest Construction Market Insights: Americas report. Growth is being underpinned by major public programs, AI-focused digital infrastructure funding, and continued investment in biomanufacturing, vaccines, therapeutics, and research facil

Tuesday, June 23, 2026

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. “On behalf of the entire Board of Directors, we are

Monday, June 22, 2026

New labour market intelligence service for the bio-economy launched

OTTAWA, Ontario--(BUSINESS WIRE)-- #ait--Today, BioTalent Canada launched BioInsights, its new labour market intelligence (LMI) consulting service for the bio-economy — the essential decision intelligence resource for strategic planning, competitive advantage, attracting new investment, future growth ambitions and effective talent management. BioInsights is a professional LMI consulting service that is informed by BioTalent Canada’s multi-year data gathering, analysis and trends customized to individu

Monday, June 22, 2026

BIOTECanada Opens Canada Pavilion at BIO 2026 Amid Major Policy Momentum for Canadian Biotech

OTTAWA, Ontario--(BUSINESS WIRE)--BIOTECanada officially opened the Canada Pavilion today at the BIO International Convention in San Diego, serving as the central hub for Canadian biotechnology companies to showcase their strengths and connect with global partners. The opening comes at a pivotal moment for Canada’s biotechnology and life sciences sector. Over the past year, the sector has moved into the centre of several major federal priorities, from investment and tax competitiveness to healt